NSCLC - Immunogenic after all?

Journal of Thoracic Disease

Volumn 3, Issue 2, 2011, Pages 79-81

  Kallen, Karl Josef ^a   Gnad Vogt, Ulrike ^b  

^a CureVac GmbH   (Germany)

^b Nationales Zentrum für Tumorerkrankungen Heidelberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861988393     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2011.02.01     Document Type: Editorial

References (19)

1. Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, et al. Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011;3:105-14.
2. Wang Y.Y., Malik R. Safety and efficacy of talactoferrin in previously treated patients with non-small cell lung cancer (FORTIS-M). ClinicalTrials.gov registration number: NCT00707304.
3. Wang Y.Y., Malik R. Safety and efficacy of talactoferrin in addition to standard chemotherapy in patients with non-small cell lung cancer (FORTIS-C). ClinicalTrials.gov registration number: NCT00706862.
4. Spadaro M, Curcio C, Varadhachary A, Cavallo F, Engelmayer J, Blezinger P, et al. Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. Cancer Res 2007;67:6425-32.
5. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol 2008;180:6868-76.
6. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008;3:735-44.
7. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010;37:533-46.
8. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81.
9. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2007;s25:7554.
10. O'Brien ME, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, Von Pawel J, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 2004;15:906-14.
11. Stanford JL, Stanford CA, O'Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008;44:224-7.
12. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
13. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-30.
14. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40.
15. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-45.
16. Wang Y, Raghunadharao D, Raman G, Doval D, Advani S, Julka P, et al. Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial [abstract]. J Clin Oncol 2006;s24:7095.
17. Parikh PK, Wang Y, Ranade AA, Vaid AK, Advani SH, Raghunadharao D, et al. Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebocontrolled, phase 2 trial [abstract]. J Clin Oncol 2007;s25:7540.
18. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010;102:115-23.
19. Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev 2011;30:45-60.